Drugs / EURESTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05075564 | Dec 2021 → Oct 2022 | neoplasm | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EURESTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314742 ↗ |
| Known as | ES002023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05075564 ↗ |
| Action | Inhibit | “ES002023 binding to CD39 inhibits the enzyme activity of ectonucleoside triphosphate diphosphohydrolase” NCT05075564 ↗ |
| Modality | Monoclonal antibody | “ES002023 is a recombinant humanized IgG1 monoclonal antibody (mAb)” NCT05075564 ↗ |
| Route | Intravenous | “ES002023 is administered via intravenous infusion” NCT05075564 ↗ |
| Target | ENTPD1 | “ES002023 is a recombinant humanized IgG1 monoclonal antibody (mAb) that specifically targets the human ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1, CD39,...” NCT05075564 ↗ |